All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2024-07-19T09:30:37.000Z

Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up

Jul 19, 2024
Share:
Learning objective: After reading this article, learners will be able to recall the latest data and recommendations relating to ECP use in cGvHD.

Bookmark this article

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of extracorporeal photopheresis (ECP) in the management of chronic graft-versus-host disease (cGvHD).

Zinaida Perić, University of Rijeka, Rijeka, HR, shared her thoughts on patient eligibility, treatment optimization, and follow-up after treatment with ECP for cGvHD. She also discussed a case report of a patient with steroid-refractory (SR)-cGvHD, plus retrospective (Table 1) and prospective data on the use of ECP in cGvHD. In addition, she shared the Nordic ECP Quality Group treatment guidelines for SR-cGvHD.

Table 1. Retrospective data of ECP in SR-cGvHD*

ECP, extracorporeal photopheresis; SR-cGvHD, steroid-resistant chronic graft-versus-host disease.
*Data from Nygaard et al.1

 

Figure 1. Treatment guidelines proposed by the Nordic ECP Quality Group*

cGvHD, chronic graft-versus-host disease; CR, complete response; ECP, extracorporeal photopheresis; MR, minimal response; mixR, mixed response; NC, no change; PR, partial response; SR, steroid-refractory.
*Adapted from Lee et al.2

Listen to this presentation as a podcast here:

Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up

Q&A session

This symposium closed with a panel Q&A session with live audience participation, where our panelists discussed their perspectives on donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops.

Symposium | Q&A | Donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops

This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.

  1. Nygaard M, Wichert S, Berlin G, et al. Extracorporeal photopheresis for graft-vs-host disease: A literature review and treatment guidelines proposed by the Nordic ECP Quality Group. Eur J Haematol. 2020;104(5):361-375. DOI: 10.1111/ejh.13381
  2. Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984-999. DOI: 10.1016/j.bbmt.2015.02.025

Your opinion matters

HCPs, what is your preferred format for educational content on the GvHD Hub?
10 votes - 7 days left ...

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox